Dr Lal PathLabs has formed a rounding bottom pattern on weekly charts and manages to surpass above its 200 days exponential moving average on weekly interval in the recent past
Dr Lal PathLabs reported a Rs 72 crore net profit during the corresponding period of the previous year. Revenues rose 12.6% to Rs 601 crore in Q2FY24, compared to Rs 534 crore in Q2FY23.
The brokerage has a sell call on Dr Lal with a target price of ₹1,740, implying a potential downside of over 30 percent. Meanwhile, it has a reduce call on Metropolis with a target price of ₹1,350, indicating an over 7 percent downside.
Traders with medium-term investment horizons can look at buying the stock for a possible target of Rs 2,800 in 3-6 months, suggested experts. The stock rose from Rs 1,841 on 3 April 2023 to Rs 2517 recorded on 3 October 2023. This translates into an upside of 36% in the last 6 months. It rose over 13% in a month